Accelerate your biotech company, startup, or university’s innovation portfolio at our Astellas 2022 Pharma Day on February 8.
MassBio’s Pharma Days®
are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies.
Discover on February 8 |
Join Astellas’ open information session on February 8 for the latest insights on its R&D strategy, target therapeutic areas, and partnering capabilities. This session will be followed by a networking reception. This session will feature:
Please note: MassBio is taking all appropriate precautions while also closely monitoring the latest public health guidance on COVID-19. Accordingly, all attendees for this event are required to be fully vaccinated.
Connect on February 8 |
- Hide Goto, Ph.D., President, Astellas Institute for Regenerative Medicine
- Michael Luther, Ph.D., MBA, Head of Early Stage Partnering, Astellas
- Michael Patane, Ph.D., President, Mitobridge
- Mat Pletcher, Ph.D., Division Head of Gene Therapy Research & Technical Operations, Astellas Gene Therapies
- Joanna Stanicka, Ph.D., CEO and Founder, Axonis
Innovators with small molecule, gene therapy, mRNA, or cell therapy candidates or technology in the therapeutic areas listed below who are actively looking for licensing opportunities are encouraged to apply for a one-on-one meeting with Astellas representatives. Astellas’ target therapeutic areas are:
• Mitochondria Biology
Applications for one-on-one meetings can be found here
, and must be submitted by January 7, 2022 at 12:00AM
Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with State of Possible partners. Please note that these partners did NOT sign Non-Disclosure Agreements (NDAs). Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed.
Please note that this will be a hybrid event, with a limited number of in-person attendees. In-person attendance is available on a first-come-first-serve basis, and all additional registrants will be placed on a waitlist. All attendees for this event are required to be fully vaccinated and masks will be required in all common areas of the event space, except while eating or drinking.